Key Highlights

  • enGene (NASDAQ:ENGN) changed hands at USD 2.16 on November 12, 2026, a gain of 20.05% from an implied prior close of about USD 1.80, with 6.33 million shares traded, roughly 5.6 times a typical session.
  • The advance followed a November 11 LEGEND trial update, in which 56% of 120 evaluable patients reached a complete response at some point.
  • The company plans to open a rolling Biologics License Application for detalimogene by the end of 2026 and sees potential approval during 2027.
  • A brokerage raised its rating on the shares to an overweight equivalent on November 12, which added to Demand during the session.

The Catalyst: Longer-Lasting Responses in LEGEND

enGene (NASDAQ:ENGN) is developing detalimogene, a non-viral gene therapy placed directly into the bladder for people with non-muscle invasive bladder cancer that has stopped responding to BCG, the standard immunotherapy. The November 11 update used an October 29, 2026 data cutoff and included 120 of the 125 patients enrolled, all of them evaluable. The complete response rate at any time climbed to 56% from 54% at the prior update. Durability was the real improvement: responses still held at the one-year mark reached 24%, up from 13%, while the share of responders still responding at 12 months rose to 43% from 25%. Median response length grew to 10.1 months from 8.6. Roughly 97% of evaluable patients had no progression toward invasive disease, and 86% kept their bladder, among them 96% of responders. Better durability answers the main worry investors voiced after earlier readouts.

Filing Timeline, Safety and the Upgrade

The company is aiming to begin its rolling submission before year-end, finish it during the first half of 2027, and possibly secure approval during 2027. Tolerability also fits that timetable. Drug-linked side effects were seen in 59% of patients, largely Grade 1 or 2, while 4% had Grade 3 effects, 2% had serious drug-linked events, and nobody reached Grade 4 or 5. Because it is non-viral, the therapy is easier to make and handle than viral gene therapies and can be given in a urology office, which may help uptake at community practices. On November 12 a brokerage moved the shares up to an overweight equivalent, pointing to the stronger data. Stronger staying power, a defined submission path and the favorable rating change combined to draw purchasers into the session, where trading ran far beyond the typical pace. A mid-2027 update is also scheduled for a cohort using a bladder rinse intended to boost uptake of the treatment.

Valuation, Competition and Open Questions

At USD 2.16, enGene (NASDAQ:ENGN) carried a Market Value of about USD 144.82 million on the screen, with trailing diluted losses of USD 2.08 per share and no product sales. As a clinical-stage business, it will need funding to assemble a commercial team and bring the product to market, so dilution stays part of the thesis. Therapies for patients who no longer respond to BCG are increasingly contested, as several products are already cleared or close to clearance, and certain rivals cite higher durable response figures. The 24% complete response at 12 months is the figure doctors and regulators will compare. The study lacks a control group, a common design here, so comparisons with other trials stay contestable. Shareholders should monitor the start of the filing, longer follow-up, any alliance with a larger oncology firm and the company's cash runway disclosures.

Where Things Stand

enGene (NASDAQ:ENGN) climbed 20.05% to USD 2.16 on November 12, 2026, after LEGEND figures showed a 56% complete response rate and clearly stronger durability, alongside a plan to begin its BLA by year-end and a rating upgrade. The gentle safety profile backs the filing. Funding needs, rival therapies and the 24% 12-month response rate remain the central debates as the company heads toward a possible 2027 approval.